1. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986;8:283–298.
2. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434–438.
3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202–1219.
4. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048–1058.
5. Bacon BR, Farahvish MJ, Janney CG, et al. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103–1109.
6. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137–145.
7. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–1419.
8. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710–723.
9. Chitturi S, George J. NAFLD/NASH is not just a ‘Western’ problem: some perspectives on NAFLD/NASH from the East. In: Farrell GC, George J, Hall P, et al., eds. Fatty liver disease; NASH and related disorders. Malden, MA: Blackwell Science, 2005:218.
10. Marx J. Unraveling the causes of diabetes. Science 2002;296:686–689.
11. Becker U, Deis A, Sorensen TIA, et al. Prediction of liver disease by alcohol intake, sex and age: a prospective population study. Hepatology 1996;23:1025–1029.
12. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112–117.
13. Ferrell GC, George J, Hall P, et al. Overview: an introduction to NASH and related fatty liver disorders. In: Farrell GC, George J, Hall P, et al., eds. Fatty liver disease; NASH and related disorders. Malden, MA: Blackwell Science, 2005:4.
14. Cairns SR, Peters TJ. Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. Clin Sci 1983;65:645–652.
15. Teli MR, James OFW, Burt AD, et al. The natural history of nonalcoholic fatty liver: a followup study. Hepatology 1995;22:1714–1719.
16. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004;24:3–20.
17. Lee RG. Nonalcoholic steatohepatitis: tightening the screws on a hepatic rambler. Hepatology 1995;21:1742–1743.
18. Itoh S, Youngel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987;82:650–654.
19. Cortez-Pinto H, Baptista A, Camilo ME, et al. Nonalcoholic steatohepatitis. Dig Dis Sci 1996;41:172–179.
20. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. Gastroenterology 1988;95:1056–1062.
21. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998;15:246–258.
22. Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: an assessment of variability in pathological interpretation. Mod Pathol 1998;11:560–565.
23. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999;94:2467–2474.
24. Mendler MH, Kanel G, Govindarajan S. Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int 2005;25:294–304.
25. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74–80.
26. Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995;20:127–130.
27. Schaffner F, Popper H. Capillarization of hepatic sinusoids. Gastroenterology 1963;44:239–242.
28. Nosadini R, Avogaro A, Mollo F, et al. Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow. J Clin Endocrinol Metab 1984;58:1125–1132.
29. Matsui O, Kadoya M, Takahashi S, et al. Focal sparing of segment IV in fatty livers shown by sonography and CT: correlation with aberrant gastric venous drainage. Am J Roentgenol 1995;164:1137–1140.
30. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664–669.
31. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689–692.
32. Kodali VP, Gordon SC, Silverman AL, et al. Cryptogenic liver disease in the United States: further evidence for non-A, non-B, non-C hepatitis. Am J Gastroenterol 1994;89:1836–1839.
33. Saunders JB, Walters JR, Davies AP, et al. A twenty year prospective study of cirrhosis. Br Med J 1981;282:263–266.
34. DiBisceglie AM, Bacon BR, Neuschwander-Tetri BA, et al. Role of hepatitis G virus in cryptogenic liver disease. Gastroenterology 1996;110:A1181.
35. Strauss E, Lacet CMC, Caly WR, et al. Cryptogenic cirrhosis: clinical-biochemical comparison with alcoholic and viral etiologies. Arch Gastroenterol 1990;27:46–52.
36. Mendiola AE, Gish RG. Risk factors for NASH in patients with cryptogenic cirrhosis. Gastroenterology 2001;120:A545.
37. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an under-recognized cause of cryptogenic cirrhosis. JAMA 2003;289:3000–3004.
38. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of nonalcoholic fatty liver disease. J Hepatol 2004;40:578–584.
39. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363–373.
40. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and post-transplantation non-alcoholic fatty liver disease. Liver Transpl 2001;7:797–801.
41. Ayata G, Gordon FD, Lewis WD, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002;33:1098–1104.
42. El-Hassan AY, Ibrahim EM, Al-Mulhim FA, et al. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 1992;65:774–778.
43. Gale ME, Gerzof SG, Robbins AH. Portal architecture: a differential guide to fatty infiltration of the liver on computerized tomography. Gastrointest Radiol 1983;8:231–236.
44. Mochizuki S, Makita T. A possible role of a blood vessel in formation of the fat area in the quadrate lobe of procine liver. J Vet Med Sci 1997;59:341–345.
45. Grove A, Vyberg B, Vyberg M. Focal fatty change in the liver. Virchows Arch Pathol Anat 1991;419:69–75.
46. Burrows CJ, Jones AW. Hepatic subcapsular steatosis in a patients with insulin dependent diabetes receiving dialysis. J Clin Pathol 1994;47:274–275.
47. Bashist B, Hecht HL, Harley WD. Computed tomographic demonstration of rapid changes in in fatty infiltration of the liver. Radiology 1982;142:691–692.
48. Mulhern CB, Arger PH, Coleman BG, et al. Nonuniform attenuation in computed tomography study of the cirrhotic liver. Radiology 1979;132:399–402.
49. Bockus HL. Gastro-enterology, Vol III Philadelphia, PA: WB Saunders, 1946:385–392.
50. Budd George. On diseases of the liver. Philadelphia, PA: Lea & Blanchard, 1846:227. University of Virginia Historical Collection.
51. Morgan William. The liver and its diseases, both functional and organic. Their history, anatomy, chemistry, pathology, physiology, and treatment. London: Homeopathic Publishing Company, 1877:144. University of Virginia Historical Collection.
52. Zelman S. The liver in obesity. Arch Intern Med 1958;90:141–156.
53. Payne JH, DeWind LT, Commons RR. Metabolic observations in patients with jejunocolic shunts. Am J Surg 1963;106:273–289.
54. Moxley RT, Pozefsky T, Lockwood DH. Protein nutrition and liver disease after jejunoileal bypass for morbid obesity. N Engl J Med 1974;290:921–926.
55. McGill DB, Humphreys SR, Baggenstoss AH, et al. Cirrhosis and death after jejunoileal shunt. Gastroenterology 1972;63:872–877.
56. Bondar GF, Pisesky W. Complications of small intestinal short circuiting for obesity. Arch Surg 1967;94:707–716.
57. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass: prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982;82:535–548.
58. Faloon WW. Hepatobiliary effects of obesity and weight-reducing surgery. Semin Liver Dis 1988;8:229–236.
59. Hayashi PH, Harrison SA, Torgerson S, et al. Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related. Am J Gastroenterol 2004;99:76–81.
60. Iturriage H, Bunout D, Hirsch S, et al. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutr 1988;47:235–238.
61. Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25:108–111.
62. Purohit V, Russo D, Coates PM. Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of symposium. Alcohol 2004;34:3–8.
63. Diehl AM. Obesity and alcoholic liver disease. Alcohol 2004;34:81–87.
64. Dixon JB, Bathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91–100.
65. Davies MJ, Baer DJ, Judd JT, et al. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women. JAMA 2003;287:2559–2562.
66. Sanderson SO, Smyrk TC. The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens. Am J Clin Pathol 2005;123:503–509.
67. Pinto HC, Baptista A, Camilo ME, et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172–179.
68. Mihas AA, Tavassoli M. Laboratory markers of ethanol intake and abuse: a critical appraisal. Am J Med Sci 1992;303:415–428.
69. Perseghin G, Mazzaferro V, Sereni LP, et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology 2000;31:694–703.
70. Petrides AS. Liver disease and diabetes mellitus. Diab Res 1994;2:2–18.
71. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 1967;2:1051–1056.
72. Petrides AS, Stanley T, Matthews DE, et al. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 1998;28:141–149.
73. Jacobsen EB, Hamberg O, Quistorff B, et al. Reduced mitochondrial adenosine triphosphate synthesis in skeletal muscle in patients with Child-Pugh class B and C cirrhosis. Hepatology 2001;34:7–12.
74. Byron D, Minuk GY. Profile of an urban hospital-based practice. Hepatology 1996;24:813–815.
75. Hilden M, Christoffersen P, Juhl E, et al. Liver histology in a ‘normal’ population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977;12:593–597.
76. Sorbi D, McGill DB, Thistle JL, et al. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 2000;95:3206–3210.
77. Kim WR, Brown RS, Terrault NA, et al. Burden of liver disease in the Unites States: summary of a workshop. Hepatology 2002;36:227–242.
78. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960–967.
79. Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142–149.
80. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology 2005;42:44–52.
81. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003;124:248–250.
82. Mathieson UL, Franzen LE, Fryden A, et al. The clinical significance of slightly too moderately elevated liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999;34:85–91.
83. Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999;94:3010–3014.
84. Navarro VJ, St Louis T, Bell BZ, et al. Chronic liver disease in the primary care practices of Waterby, Connecticut. Hepatology 2003;38:1062.
85. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356–1362.
86. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106–1110.
87. Andersen T, Gluud C. Liver morphology in morbid obesity: a literature study. Int J Obes 1984;8:97–106.
88. Andersen T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical, morphological and biochemical study. Int J Obes 1984;8:107–115.
89. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117–1123.
90. Garcia-Monzon C, Martin-Perez E, Lo Iacono O, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000;33:716–724.
91. Braillon A, Capron JP, Herve MA, et al. Liver in obesity. Gut 1985;26:133–139.
92. Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005;15:310–315.
93. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450–455.
94. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183–1192.
95. Falchuk KR, Fiske SC, Haggitt RC, et al. Pericentral hepatic fibrosis and intracellular hyaline in diabetes mellitus. Gastroenterology 1980;78:535–541.
96. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity. Pathol Annu 1989;24:275–302.
97. Sundaram V, Nadkarni M, Riddle RK, et al. Risk factors of nonalcoholic fatty liver disease in a large cohort of non-insulin dependent diabetic patients. Hepatology 2005;42:627A.
98. Batman PA, Scheuer PJ. Diabetic hepatitis preceding the onset of glucose intolerance. Histopathology 1985;9:237–243.
99. Silverman JF, O’Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1349–1355.
100. de Marco R, Locatelli F, Zoppini G, et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diab Care 1999;22:756–761.
101. Tolman KG, Fonseca V, Tan MH, et al. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004;141:946–956.
102. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262–265.
103. Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000;45:1929–1934.
104. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373–379.
105. McCullough AJ. The clinical features, diagnosis, and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:521–533.
106. Caldwell SH, Zaidman JS, Hespenheide EE. The liver and statin drug therapy: uncertain navigation in the sea of risk-benefit. Pharmacoepidemiol Drug Saf 2003;12:303–306.
107. Adams LA, Lindor KD. Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought. Indian J Gastroenterol 2004;23:127–128.
108. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005;41:690–695.
109. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62–65.
110. Park Y-W, Zhu S, Palaniappan L, et al. The metabolic syndrome. Arch Intern Med 2003;163:427–436.
111. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005;329:111–116.
112. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367–372.
113. Bugianesi E, Zannoni C, vanni E, et al. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 2003;36:165–173.
114. Nguyen-Duy T-B, Nichaman MZ, Church TS, et al. Visceral and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab 2003;284:E1065–E1071.
115. Kelley DE, McKolanis TM, Hegazi RAF, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285:E916–E916.
116. Lee JH, Rhee PL, Lee JK, et al. Role of hyperinsulinemia and glucose intolerance in the pathogenesis of nonalcoholic fatty liver in patients with normal body weight. Korean J Intern Med 1998;13:12–14.
117. Banerji MA, Faridi N, Atluri R, et al. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:137–144.
118. Reaven GM. Role of insulin resistance in human diabetes. Diabetes 1988;37:1595–1607.
119. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diab Care 1991;14:173–194.
120. Bjorntorp P. Abdominal obesity and the development of noninsulin-dependent diabetes mellitus. Diab Metab 1988;4:622–627.
121. Lonardo A. Fatty liver and nonalcoholic steatohepatitis: where do we stand and where are we going? Dig Dis 1999;17:80–89.
122. Hsich SD, Yoshinaga H. Is there any difference in coronary heart disease risk factors and prevalence of fatty liver in subjects with normal body mass index having different physiques? Tohoku J Exp Med 1995;177:223–231.
123. Kral JG, Schaffner F, Pierson RN, et al. Body fat topography as an independent predictor of fatty liver. Metabolism 1993;42:548–551.
124. Ruderman N, Chisolm D, Pi-Sunyer X, et al. The metabolically obese, normal-weight individual revisited. Diabetes 1998;47:699–713.
125. Moran JR, Ghishan FK, Halter SA, et al. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 1983;78:374–377.
126. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641–649.
127. Kinugasa A, Tsunamoto K, Furukawa N, et al. Fatty liver and its fibrosis changes found in simple obesity in children. J Pediatr Gastroenterol Nutr 1984;3:408–414.
128. Baldridge AD, Perez-Atayde AR, Graerne-Cook F, et al. Idiopathic steatohepatitis in children: a multicenter retrospective study. J Pediatr 1995;127:700–704.
129. Molleston JP. The histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:536–538.
130. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000;30:48–53.
131. Schwimmer JB, Deutsch R, Rauch JB, et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003;143:500–505.
132. Schwimmer JB, McGreal N, Deutsch R, et al. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005;115:561–565.
133. Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histological features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003;16:49–56.
134. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997;78:1527–1531.
135. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotypes and visceral adiposity. Hepatology 2001;33:1358–1364.
136. Weinman SA, Belalcazar LM. Hepatitis C: a metabolic liver disease. Gastroenterology 2004;126:917–919.
137. Sud A, Hui JM, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004;39:1239–1247.
138. Negro F. Hepatitis C virus and liver steatosis: when fat is not beautiful. J Hepatol 2004;40:533–535.
139. Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003;98:2064–2071.
140. Solis-Herruzo JA, Perez-Carreras M, Rivas E, et al. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 2005;100:1091–1098.
141. Bonkovsky H, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999;31:421–429.
142. George D, Goldwurm S, MacDonald G, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311–318.
143. Powell EE, Jonsson JR, Clouston AD. Steatosis: Co-factor in other liver diseases. Hepatology 2005;42:5–13.
144. Caldwell SH, Harris DM, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastroenterol 2002;97:1496–1500.
145. Santos L, Molina EG, Jeffers LJ, et al. Prevalence of nonalcoholic steatohepatitis among ethnic groups. Gastroenterology 2001;120:A630.
146. Squires RH, Lopez MJ. Steatohepatitis is a serious condition in Hispanic children. Hepatology 2000;32:A418.
147. Kemmer NM, McKinney KH, Xiao S-Y, et al. High prevalence of NASH among Mexican American females with type II diabetes mellitus. Gastroenterology 2001;120:A117.
148. Resnick HE, Valsania P, Halter JB, et al. Differential effects of BMI on diabetes risk among black and white Americans. Diab Care 1998;21:1828–1835.
149. Perry AC, Applegate EB, Jackson ML, et al. Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables. J Appl Physiol 2000;89:636–643.
150. Yanoyski JA, Yanovski SZ, Filmer KM, et al. Differences in body composition of black and white girls. Am J Clin Nutr 1996;64:833–839.
151. Dowling HJ, Pi-Sunyer FX. Race-dependent health risks of upper body obesity. Diabetes 1993;42:537–543.
152. Mahmood S, Taketa K, Imai K, et al. Association of fatty liver with increased ratio of visceral to subcutaneous adipose tissue in obese men. Acta Med Okayama 1998;52:225–231.
153. Perseghin G, Scifo P, Pagliato E, et al. Gender factors affect fatty acids-induced insulin resistance in nonobese humans: effects of oral steroidal contraception. J Clin Endocrinol Metab 2001;86:3188–3196.
154. Samaras K, Spector TD, Nguyen TV, et al. Independent genetic factors determine the amount and distribution of fat in women after the menopause. J Clin Endocrinol Metab 1997;82:781–785.
155. Carey DP, Nguyen TV, Campbell LV, et al. Genetic influences on central abdominal fat: a twin study. Int J Obes Relat Metab Disord 1996;20:722–726.
156. Laws A, Stefanick ML, Reaven GM. Insulin resistance and hypertriglyceridemia in nondiabetic relatives of patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989;69:343–347.
157. Lillioja S, Mott DM, Zawadzki JA, et al. In vivo insulin action is familial characteristic in nondiabetic Pima Indians. Diabetes 1987;36:1329–1335.
158. Sumner AE, Finley KB, Genovese DJ, et al. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med 2005;165:1395–1400.
159. Browning JD, Kumar KS, Saboorian MH, et al. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004;99:292–298.
160. Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005;41:372–379.
161. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–1395.
162. Struben VMD, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000;108:9–13.
163. Willner IR, Waters B, Patil SR, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957–2961.
164. Maddrey WC, Iber FL. Familial cirrhosis. Ann Intern Med 1964;61:667–679.
165. Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of diabetes with type 2 diabetes. N Engl J Med 2004;350:664–671.
166. Day CP. The potential role of genes in nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:673–692.
167. Merriman RB, Aouizerat BE, Bass NM. Genetic influences in nonalcoholic fatty liver disease. J Clin Gastroenterol 2005;39(Suppl 4):S286–S289.
168. Lan H, Rabaglia ME, Stoehr JP, et al. Gene expression profiles of nondiabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes 2003;52:688–700.
169. Sreekumar R, Rosado B, Rasmussen D, et al. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003;38:244–251.
170. Trujillo KD, Vizcarra SN, Lopez RO, et al. Non-alcoholic steatohepatitis related to morbid obesity: genetic and clinical risk factors. Gastroenterology 2005;128:A542.
171. Merriman RB, Aouizerat BE, Yankovich M, et al. Variants of adipocyte genes affecting free fatty acid flux in patients with nonalcoholic fatty liver disease. Hepatology 2003;34:A508.
172. Huang H, Merriman RB, Chokkalingam AP, et al. Novel genetic markers associated with risk of non-alcoholic fatty liver disease. Gastroenterology 2005;128:A684.
173. Aitman TJ. CD36, insulin resistance, and coronary heart disease. Lancet 2001;357:651–652.
174. Miyaoka K, Kuwasako T, Hirano K, et al. CD36 deficiency associated with insulin resistance. Lancet 2001;357:686–688.
175. Mendler M-H, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117:1155–1163.
176. Hegele RA, Anderson CM, Wang J, et al. Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes. Genome Res 2000;10:652–658.
177. Capel ID, Dorrell HM. Abnormal antioxidant defense in some tissues of congenitally obese mice. Biochem J 1984;219:41–49.
178. Watson AM, Poloyac SM, Howard G, et al. Effect of leptin on cytochrome p-450, conjugation and anti-oxidant enzymes in the ob/ob mouse. Drug Metab Dispos 1999;27:695–700.
179. Sastre J, Pallardo FV, Liopos J, et al. Glutathione depletion by hyperphagia-induced obesity. Life Sci 1989;45:183–187.
180. Strauss RS. Comparison of serum concentrations of α-tocopherol and β-carotene in a cross-sectional sample of obese and non-obese children (NHANES III). J Pediatr 1999;134:160–165.
181. Lee M, Hyun D, Halliwell B, et al. Effect of the over expression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 2001;76:998–1009.
182. Lee M, Hyun D, Jenner P, et al. Effect of over-expression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defenses: relevance to Down’s syndrome and familial amyotrophic lateral sclerosis. J Neurochem 2001;76:957–965.
183. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828–833.
184. Dixon JB, Bhathal PS, Jonsson JR, et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 2003;39:967–971.
186. Diehl AK. Cholelithiasis and the insulin resistance syndrome. Hepatology 2000;31:528–530.
187. Chatila R, West AB. Hepatomegaly and abnormal liver tests due to glycogenosis in adults with diabetes. Medicine 1996;75:327–333.
188. Randall B. Sudden death and hepatic fatty metamorphosis: A North Carolina Survey. JAMA 1980;293:1723–1725.
189. Caldwell SH, Hespenheide EE. Subacute liver failure in obese females. Am J Gastroenterol 2002;97:2058–2062.
190. Cortez-Pinto H, Camilo ME, Baptista A, et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome. Clin Nutr 1999;18:353–358.
191. Knobler H, Schatter A, Zhornicki T, et al. Fatty liver— an additional and treatable feature of the insulin resistance syndrome. QJM 1999;92:73–79.
192. Ikai E, Ishizaki M, Suzuki Y, et al. Association between hepatic steatosis, insulin resistance, and hyperinsulinemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995;9:101–105.
193. Lobo RA, Carmino E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989–993.
194. Chalasani N, Deeg MA, Persohn S, et al. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:1849–1855.
195. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844–1850.
196. Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: a cool look at a burning issue. Gastroenterology 2001;120:1281–1285.
197. Sanyal AJ. Insulin resistance and nonalcoholic steatohepatitis: fat or fiction. Am J gastroenterol 2001;96:274–276.
198. Kuczmarski RJ. Need for body composition information in elderly subjects. Am J Clin Nutr 1989;50:1150–1157.
199. Crawford DH, Shepherd RW, Halliday JW, et al. Body composition in nonalcoholic cirrhosis: the effect of disease etiology and severity on nutritional compartments. Gastroenterology 1994;106:1611–1617.
200. Mertens I, Van Gaal LF. Visceral fat as a determinant of fibrinolysis and hemostasis. Semin Vasc Med 2005;5:48–55.
201. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473–480.
202. McPherson DD. Circulatory dysfunction in NAFLD— which is first, which is last and what do we do in between? Hepatology 2005;42:270–272.
203. Harrison SA, Neuschwander-Tetri B. Clinical manifestations and diagnosis of NAFLD. In: Farrell GC, George J, Hall P, et al., eds. Fatty liver disease; NASH and related disorders. Malden, MA: Blackwell Science, 2005:159.
204. Fletcher LM, Kwoh-Gain I, Powell EE, et al. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: an aid to diagnosis. Hepatology 1991;13:455–459.
205. Nanji AA, French SW, Freeman JB. Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 1986;36:266–269.
206. Mofrad P, Contos MJ, Haque M, et al. Clinical and histological spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286–1292.
207. Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease— a clinical-histological study. J Hepatol 2004;41:751–757.
208. Kronenberger B, Lee JH, Ruster B, et al. Reduced hepatocellular turnover in patients chronically infected with hepatitis C virus and persistently normal ALT levels. Hepatology 1999;30:A459.
209. Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998;27:1213–1219.
210. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:73–79.
211. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine amintransferase levels. Ann Intern Med 2002;137:1–9.
212. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005;128:24–32.
213. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519–525.
214. Nagore N, Scheuer PJ. Does a linear pattern of sinusoidal IgA deposition distinguish between alcoholic and diabetic liver disease? Liver 1988;8:281–286.
215. Koskinas J, Kenna JG, Bird GL, et al. Immunoglobulin a antibody to a 200 kilodalton cytosolic acetaldehyde adduct in alcoholic hepatitis. Gastroenterology 1992;103:1860–1867.
216. Caldwell SH, Hespenheide EE. Obesity and cryptogenic cirrhosis. In: Leuschner U, James O, Dancygier H, eds. Steatohepatitis (ASH and NASH). Falk Symposium 121. Norwell, MA: Kluwer Academic Publishers, 2001:151.
217. Tumiel M, Whitcomb BJ, Krawitt EL. Circulating antinuclear antibodies in patients with nonalcoholic steatohepatitis. Hepatology 1994;20:A409.
218. Cotler SJ, Kanji K, Keshavarzian A, et al. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol 2004;38:801–804.
219. Younossi ZM, Gramlich T, Bacon B, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999;30:847–850.
220. Caldwell SH, Han K, Hess CE. Thrombocytopenia and unrecognized cirrhosis. Ann Intern Med 1997;127:572–573.
221. Garg A. Lipodystrophies. Am J Med 2000;108:143–152.
222. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004;350:1220–1234.
223. Phan J, Reue K. Lipin, a lipodystrophy and obesity gene. Cell Metab 2005;1:73–83.
224. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005;41:753–760.
225. N Engl J Med. Case records of the Massachusetts General Hospital. 1975;292:35–41.
226. Chandalia M, Garg A, Vuitch F, et al. Postmortem findings in generalized lipodystrophy. J Clin Endocrinol Metab 1995;80:3077–3081.
227. Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989;97:1022–1024.
228. Pardini VC, Victoria IM, Rocha SM, et al. Leptin levels, beta cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatrophic diabetes. J Clin Endocrinol Metab 1998;83:503–508.
229. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999;31:430–434.
230. Schon EA, Bonilla E, DiMauro S. Mitochondrial DNA mutations and pathogenesis. J Bioenerg Biomembr 1997;29:131–149.
231. Sozo A, Arrese M, Glasinovic JC. Evidence of intestinal bacterial overgrowth in patients with NASH. Gastroenterology 2001;120:A118.
232. Al-Osaimi AM, Berg CL, Caldwell SH. Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis. Hepatology 2005;41:943.
233. Feliciani C, Amerio P. Madelung’s disease: inherited from an ancient Mediterranean population? N Engl J Med 1999;340:1481.
234. Vila MR, Gamez J, Solano A, et al. Uncoupling protein-1 m RNA expression in lipomas from patients bearing pathogenic mitochondrial DNA mutations. Biochem Biophys Res Commun 2000;278:800–802.
235. Guillausseau P-J, Massin P, Dubois-LaForgue D, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med 2001;134:721–728.
236. Bohan A, Droogan O, Nolan N, et al. Mitochondrial DNA abnormalities without significant deficiency of intramitochondrial fatty acid β-oxidation enzymes in a well-defined subgroup of patients with nonalcoholic steatohepatitis (NASH). Hepatology 2000;32:A387.
237. Carrozzo R, Hirano M, Fromenty B, et al. Multiple mtDNA deletions features in autosomal dominant and recessive diseases suggest distinct pathogeneses. Neurology 1998;50:99–106.
238. Johns DR. Mitochondrial DNA and disease. N Engl J Med 1995;333:638–644.
239. Holt IJ, Harding AE, Petty RKH, et al. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990;46:428–433.
240. Wasserman JM, Thung SN, Berman R, et al. Hepatic Weber-Christian disease. Semin Liver Dis 2001;21:115–118.
241. Kimura H, Kako M, Yo K, et al. Alcoholic hyalins (Mallory bodies) in a case of Weber-Christian disease: electron microscopic observations of liver involvement. Gastroenterology 1980;78:807–812.
242. Amarapurkar DN, Patel ND, Amarapurkar AD. Panniculitis and liver disease (hepatic Weber Christian disease). J Hepatol 2005;42:146–152.
243. Siegelman ES, Rosen MA. Imaging of steatosis. Semin Liver Dis 2001;21:71–80.
244. Keller C, Thomas KT. Measurement of body fat and fat distribution. J Nurs Meas 1995;3:159–174.
245. Van der Kooy K, Seidell JC. Techniques for the measurements of visceral fat: a practical guide. Int J Obes 1993;17:187–196.
246. Clasey JL, Bouchard C, Wideman L, et al. The influence of anatomical boundaries, age and sex on the assessment of abdominal visceral fat. Obes Res 1997;5:395–401.
247. Kvist H, Chowdhury B, Granfard U, et al. Total and visceral adipose-tissue volumes derived from measurements with computerized tomography in adult men and women: predictive equations. Am J Clin Nutr 1988;48:1351–1361.
248. Ross R, Leger L, Morris D, et al. Quantification of adipose tissue by MRI: relationship with anthropometric variable. J Appl Physiol 1992;72:787–795.
249. Abate N, Burns D, Peshock RM, et al. Estimation of adipose tissue mass by magnetic resonance imaging: validation against dissection in human cadavers. J Lipid Res 1994;35:1490–1496.
250. Tornaghi G, Raiteri R, Pozzato C, et al. Anthropometric or ultrasonic measurements in assessment of visceral fat? A comparative study. Int J Obes 1994;18:771–775.
251. Colli A, Fraquelli M, Andreoletti M, et al. Severe liver fibrosis or cirrhosis: accuracy of US for detection – analysis of 300 cases. Radiology 2003;227:89–94.
252. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745–750.
253. Quinn SF, Gosink BB. Characteristic sonographic signs of hepatic fatty infiltration. AJR Am J Roentgenol 1985;145:753–755.
254. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986;292:13–15.
255. Joesh AE, Saverymuttu SH, al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43:26–31.
256. Sanford NL, Walsh P, Matis C, et al. Is ultrasonography useful in the assessment of diffuse parenchymal liver disease? Gastroenterology 1985;89:186–191.
257. Celle G, Savarino V, Picciotto A, et al. Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. Dig Dis Sci 1988;33:467–471.
258. Kissin CM, Bellamy EA, Cosgrove DO, et al. Focal sparing in fatty infiltration of the liver. Br J Radiol 1986;59:25–28.
259. Roffsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR 1995;16:16–33.
260. Jacobs JE, Birnbaum BA, Shapiro MA, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol 1998;171:659–664.
261. Alpern MB, Lawson TL, Foley DW, et al. Focal hepatic masses and fatty infiltration detected by enhanced dynamic CT. Radiology 1986;158:45–49.
262. Johnston RJ, Stamm ER, Lewin JM, et al. Diagnosis of fatty infiltration of the on contrast enhanced CT: limitations of liver-minus-spleen attenuation difference measurements. Abdom Imaging 1998;23:409–415.
263. Stark DD, Bass NM, Moss AA, et al. Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology 1983;148:743–751.
264. Levenson H, Greensite F, Hoefs J, et al. Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5 T vs biopsy. AJR Am J Roentgenol 1991;156:307–312.
265. Fishbein MH, Gardner KG, Potter CJ, et al. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 1997;15:287–293.
266. Lee J, Dixon TW, Ling D, et al. Fatty Infiltration of the liver: demonstration by proton spectroscopic imaging. Radiology 1984;153:195–201.
267. Dixon TW. Simple proton spectroscopic imaging. Radiology 1984;153:189–194.
268. Thomsen C, Becker U, Winkler K, et al. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994;12:487–495.
269. Ratziu V, Charlotte F, Heurtier A, et al. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;125:1898–1906.
270. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659–1664.
271. Changani KK, Fuller BJ, Bell JD, et al. Bioenergetic targeting during organ preservation: (31) P magnetic resonance spectroscopy investigations into the use of fructose to sustain hepatic ATP turnover during cold hypoxia in porcine livers. Cryobiology 2000;41:72–87.
272. Subbanagounder G, Watson AD, Berliner JA. Bioactive products of phospholipid oxidation: isolation, identification, measurement and activity. Free Radic Biol Med 2000;28:1751–1761.
273. Schlemmer H-P, Sawatzki T, Sammet S, et al. Hepatic phospholipids in alcoholic liver disease assessed by proton-decoupled 31P magnetic resonance spectroscopy. J Hepatol 2005;42:752–759.
274. Jalan R, Taylor-Robinson SD, Hodgson HJF. In vivo hepatic magnetic resonance spectroscopy: clinical or research tool?. J Hepatol 1996;25:414–424.
275. Solga SF, Horska A, Clark JM, et al. Hepatic 31P magnetic resonance spectroscopy: a hepatologist’s user guide. Liver Int 2005;25:490–500.
276. Costanzo M, Miele L, Di Rocco P, et al. Serum markers of fibrogenesis and fibrosis in nonalcoholic steatohepatitis. Hepatology 2002;36:A412.
277. Iijima H, Moriyasu F, Tsuchiya K, et al. Diagnosis of NASH using kupffer imaging of contrast enhanced ultrasound. Hepatology 2003;34:A514.
278. Ratziu V, Le Calvez S, Imber-Bismut F, et al. Diagnostic value of biochemical markers (Fibrotest) for the prediction of liver fibrosis in patients with NAFLD. Hepatology 2003;34:A510.
279. Osifo BOA, Boledeoku JD. Serum aspartate and alanine aminotransferase activities in protein energy malnutrition. Enzyme 1982;28:300–304.
280. Kallei L, Hahn A, Roder VZ. Correlation between histological findings and serum transaminase values in chronic diseases of the liver. Acta Med Scand 1964;175:49–56.
281. Marceau P, Biron S, Hould F-S, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513–1517.
282. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473–478.
283. Yu AS, Keefe EB. Elevated AST or ALT in nonalcoholic fatty liver disease: accurate predictor of disease? Am J Gastroenterol 2003;98:955–956.
284. Noaguchi H, Tazawa Y, Nishinomiya F, et al. The relationship between serum transaminase activity and fatty liver in children with simple obesity. Acta Paediatr Jpn 1995;37:621–625.
285. Harrison SA, Oliver DA, Torgerson T, et al. NASH: clinical assessment of 501 patients from two separate academic centers with validation of a clinical scoring system for advanced fibrosis. Hepatology 2003;34:A511.
286. Albano E, Mottaran E, Vidali M, et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005;54:987–993.
287. Ryan MC, Best JD, Wilson AM, et al. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diab Care 2005;28:1222–1224.
288. Palekar NA, Naus R, Larson SP, et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. (Pending publication).
289. Piccinino F, Sagnelli E, Pasquale G, et al. Complication following percutaneous liver biopsy. A multicenter retrospective study on 68,276 biopsies. J Hepatol 1986;2:165–173.
290. Caldwell SH. Controlling pain in liver biopsy. Am J Gastroenterol 2001;96:1327–1329.
291. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993;118:96–98.
292. Krause WR, Caldwell SH, Hespenheide EE. Use of a hemostatic liver biopsy device to reduce bleeding: an experimental study in swine (submitted for publication).
293. Colloredo G, Guido G, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239–244.
294. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449–1457.
295. Merriman RB, Ferrell LD, Patti MG, et al. Histological correlation of paired right lobe and left lobe biopsy in morbidly obese individuals with suspected NAFLD. Hepatology 2003;38:A232.
296. Pomrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188–196.
297. Kleiner DE, Brunt EM, Van Natta ML, et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histologic scoring system for NAFLD. Hepatology 2005;41:1313–1321.
298. Pomrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for NASH. Hepatology 2004;39:188–196.
299. Ionnou GN, Weiss NS, Kowdley KV, et al. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 2003;125:1053–1059.
300. Sasaki A, Horiuchi N, Hasegawa K, et al. Mortality and causes of death in type 2 diabetic patients. Diab Res Clin Pract 1989;7:33–40.
301. Propst A, Propst T, Judmaier G, et al. Prognosis in nonalcoholic steatohepatitis. Gastroenterology 1995;108:1607.
302. Cortez-Pinto H, Baptista A, Camilo ME, et al. Nobalcoholic steatohepatitis – a long term follow-up study. Dig Dis Sci 2003;48:1909–1913.
303. Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–121.
304. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005;129:375–378.
305. Hilden M, Juhl E, Thomsen AC, et al. Fatty liver persisting for up to 33 years. Acta Med Scand 1973;194:485–489.
306. Andersen T, Gluud C, Franzmann M-B, et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224–229.
307. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222–226.
308. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594–598.
309. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003;98:2042–2047.
310. Fassio E, Alvarez E, Dominguez N, et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40:820–826.
311. Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132–138.
312. Ratziu V, Poynard T. NASH: a hidden and silent fibroser is finally revealed. J Hepatol 2005;42:12–14.
313. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420–427.
314. Ratzui V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485–1493.
315. Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150–155.
316. Moller H, Mellemgaard A, Lindvig K, et al. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994;30A:344–350.
317. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:1625–1638.
318. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroenterol 2001;96:2462–2467.
319. Ratziu V, Poynard T. Hepatocellular cancer in NAFLD. In: Farrell GC, George J, Hall P, et al., eds. Fatty liver disease; NASH and related disorders. Malden, MA: Blackwell Science: 2005:263.
320. Cotrim HP, Parana R, Braga E, et al. Nonalcoholic steatohepatitis and hepatocellular cancer: natural history? Am J Gastroenterol 2000;95:3018–3019.
321. Zen Y, Katayanagi K, Tsuneyama K, et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001;51:127–131.
322. Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Hepatol 2002;37:154–160.
323. Soga M, Kishimoto Y, Kawamura Y, et al. Spontaneous development of hepatocellular carcinomas in the FLS mice with hereditary fatty liver. Cancer Lett 2003;196:43–48.
324. Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S97–S103.
325. Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349–1354.
326. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular cancer. Gastroenterology 2002;123:134–140.
327. Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Hepatology 2002;123:375–378.
328. Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003;163:1301–1311.
329. Hu T-H, Huang CC, Lin PR, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular cancer. Cancer 2003;97:1929–1940.
330. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001;21:89–104.
331. Farrell GC. Animal models of steatohepatitis. In: Farrell GC, George J, Hall P, et al., eds. Fatty liver disease; NASH and related disorders. Malden, MA: Blackwell Science, 2005:91.
332. Nanji AA. Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin Liver Dis 2004;8:559–574.
333. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004;40:47–51.
334. Herdt TH. Ruminant adaptation to negative energy balance. Influences on the etiology of ketosis and fatty liver. Vet Clin North Am Food Anim 2000;16:215–230.
335. Nakagawa H, Oikawa S, Oohashi T, et al. Decreased serum lecithin:cholesterol acyltransferase in spontaneous cases of fatty liver in cows. Vet Res Commun 1997;21:1–8.
336. Itoh H, Tamura K, Motoi Y, et al. Serum apolipoprotein B-100 concentrations in healthy and diseased cattle. J Vet Med Sci 1997;59:587–591.
337. Scheele CW. Pathological changes in metabolism of poultry related to increasing production levels. Vet Q 1997;19:127–130.
338. Zawie DA, Garvey MS. Feline hepatic disease. Vet Clin North Am Small 1984;14:1201–1230.
339. Nicoll RG, O’Brien RT, Jackson MW. Qualitative ultrasonography of the liver in obese cats. Vet Radiol Ultrasound 1998;39:47–50.
340. Maeda H, Mori C, Kurokawa M, et al. Production of dark firm dry meat in slaughtered pigs with so-called liver degeneration characterized by yellowish discoloration and high lipid contents. Jpn J Vet Sci 1989;51:925–933.
341. Dianzani MU. Biochemical aspects of fatty liver. In: Meeks RG, Steadman SD, Bull RJ, eds. Hepatotoxicology. Boca Raton, FL: CRC Press, 1991:371.
342. Peterson TC, Neumeister M. Effect of pentoxiphyllin in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism. Immunopharmacology 1006;31:183–193.
343. Center SA, Guida L, Zanelli MJ, et al. Ultrastructural hepatocellular features associated with severe hepatic lipidosis in cats. Am J Vet Res 1993;54:724–731.
344. Zomborszky Z, Husveth F. Liver total lipids and fatty acid composition of shot red and fallow deer males in various reproduction periods. Comp Biochem Physiol A 2000;126:107–114.
345. Shteyer E, Liao Y, Muglia LJ, et al. Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice. Hepatology 2004;40:1322–1332.
346. Farrell GC. Probing prometheus: fat fueling the fire? Hepatology 2004;40:1252–1255.
347. Pelsers MM, Butler PJ, Bishop CM, et al. Fatty acid binding protein in heart and skeletal muscles of the migratory barnacle goose throughout development. Am J Physiol 1999;276:R637–R643.
348. Dzhurov A, Kostadinov KV. Histological changes in the liver of Benkovska breed geese during the fattening period. Vet Med Nauki 1981;18:76–83.
349. Schlosberg A, Elkin N, Malkinson M, et al. Severe hepatopathy in geese and broilers associated with ochratoxin in their feed. Mycopathologia 1997;138:71–76.
350. Davail S, Guy G, Andre J-M, et al. Metabolism in two breeds of geese with moderate or large overfeeding induced liver-steatosis. Comp Biochem Physiol A 2000;126:91–99.
351. Hermier D, Rousselot-Pailly D, Peresson R, et al. Influence of orotic acid and estrogen on hepatic lipid storage and secretion in the goose susceptible to liver steatosis. Biochem Bioph Acta 1994;1211:97–106.
352. Hermier D, Saadoun A, Salichon M-R, et al. Plasma lipoproteins and liver lipids in two breeds of geese with different susceptibility to heaptic steatosis: changes induced by development and forced-feeding. Lipids 1991;26:331–339.
353. Mourot J, Guy G, Lagarrigue S, et al. Role of hepatic lipogenesis in the susceptibility to fatty liver in the goose (Anser anser). Comp Biochem Physiol B 2000;126:81–87.
354. Cinti S. Adipocyte differentiation and transdifferentiation: plasticity of the adipose organ. J Endocrinol Invest 2002;25:823–835.
355. Caldwell SH. Efficacy and safety of troglitazone for lipodystrophy syndromes. Ann Intern Med 2001;134:1008.
356. Grant PJ. Obesity, adipocytes, and squirrels. Diab Vasc Dis Res 2004;1:67.
357. McGillis JP. White adipose tissue, inert no more! Endocrinology 2005;146:2154–2156.
358. Stannard SR, Johnson NA. Insulin resistance and elevated triglycerides in muscle: more important for survival than ‘thrifty’ genes? J Physiol 2004;554:595–607.
359. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2005;39:S273–S285.
360. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319–336.
361. Saleh J, Sniderman AD, Cianflone K. Regulation of plasma fatty acid metabolism. Clin Chim Acta 1999;286:163–180.
362. Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and a review of the literature. Medicine 1962;41:249–276.
363. Mavrelis PG, Ammon HV, Gleysteen JJ, et al. Hepatic free fatty acids in alcoholic liver disease and morbid obesity. Hepatology 1983;2:226–231.
364. Day CP, James OFW. Steatohepatitis: a tale of two hits. Gastroenterology 1998;114:842–845.
365. Browning JD, Horton JD. Molecular mediators of hepatic steatosis. J Clin Invest 2004;114:147–152.
366. Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver diseases. J Clin Invest 2005;115:1139–1142.
367. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331–340.
368. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343–1351.
369. Bass NM, Merriman RB. Fatty acid metabolism and lipotoxicity in the pathogenesis of NAFLD/NASH. In: Farrell GC, George J, Hall P, McCullough AJ, eds. Fatty Liver Disease; NASH and related disorders. Malden, MA: Blackwell Publishing, 2005:109.
370. Li Z, Oben JA, Yang S, et al. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 2004;40:434–441.
371. Romijn JA, Fliers E. Sympathetic and parasympathetic innervation of adipose tissue: metabolic implications. Curr Opin Clin Nutr 2005;8:440–444.
372. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004;24:99–106.
373. Boden G, Jadali F, White J, et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 1991;88:960–966.
374. Boden G, Chen X, Ruiz J, et al. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994;93:2438–2446.
375. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996;97:2859–2865.
376. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995;96:1261–1268.
377. Boden G. Role of free fatty acids in the pathogenesis of insulin resistance in NIDDM. Diabetes 1996;45:3–10.
378. Kelley DE, Mintun MA, Watkins SC, et al. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 1996;97:2705–2713.
379. Bonadonna RC, Zych K, Boni C, et al. Time dependence of the interaction between lipid and glucose metabolism in humans. Am J Physiol 1989;20:E49–E56.
380. Oehler G, Bleyl H, Matthes KJ. Hyperinsulinemia in hepatic steatosis. Int J Obes 1982;6(S1):137–144.
381. Inokuchi T, Watanabe K, Kameyama H. Altered basal C-peptide/insulin molar ratios in obese patients with fatty liver. Jpn J Med 1988;27:272–276.
382. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:575–594.
383. Yki-Jarvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med 2005;5:287–295.
384. DeFronzo RA, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and insulin resistance. Am J Physiol 1979;237:E214–E223.
385. DeFronzo RA, Gunnarsson R, Bjorkman O, et al. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin dependent diabetes mellitus. J Clin Invest 1985;76:149–155.
386. Frayne KN. Insulin resistance and lipid metabolism. Curr Opin Lipidol 1993;4:197–204.
387. DeFronzo RA. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988;37:667–687.
388. Taylor R. Causation of type 2 diabetes – the Gordian knot unravels. N Engl J Med 2004;350:639–641.
389. Yu C, Chen Y, Cline GW, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate 1 (IRS-1) associated phosphotidylinositol 3 kinase activity in muscle. J Biol Chem 2002;52:50230–50236.
390. Tribble DL, Aw TY, Jones DP. The pathophysiological significance of lipid peroxidation in oxidative cell injury. Hepatology 1987;7:377–387.
391. Recknagle RO, Glende EA, Britton RS. Free radical damage and lipid peroxidation. In: Meeks RG, Harrison SD, Bull RJ, eds. Hepatotoxicology. Boca Raton, FL: CRC Press, 1991:401–436.
392. Hruszkewycz AM. Evidence for mitochondrial DNA damage by lipid peroxidation. Biochem Biophys Res Commun 1988;153:191–197.
393. Meagher EA, Fitzgerald GA. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med 2000;28:1745–1750.
394. George J, Pera N, Phung N, et al. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003;39:756–764.
395. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 1997;26(Suppl 1):13–22.
396. Seki S, Kitada T, Sakaguchi H, et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatol 2002;37:56–62.
397. Horimoto M, Fulop P, Derdak Z, et al. Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. Hepatology 2004;39:386–392.
398. Le TH, Caldwell SH, Redick JA, et al. The lobular distribution of mitochondrial abnormalities in NASH. Hepatology 2004;39:1423–1429.
399. Chavin KD, Yang SQ, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999;274:5692–5700.
400. Yang SQ, Zhu H, Li Y, et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000;378:259–268.
401. Ikura Y, Ohsawa M, Suekane T, et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: Impact on disease progression. Hepatology 2006;43:506–514.
402. Tauchi-Sato K, Ozeki S, Houjou T, et al. The surface of lipid droplets is a phospholipid monolayer with a unique fatty acid composition. J Biol Chem 2002;277:44507–44512.
403. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467–1476.
404. Guebre-Xabier M, Yang SQ, Lin HZ, et al. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 2000;31:633–640.
405. Yang SQ, Liu HZ, Laue MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997;94:2557–2562.
406. Lee FYJ, Li Y, Zhu H, et al. Tumor necrosis factor increases mitochondrial oxidant production and induces expression of uncoupling protein-2 in the regenerating rat liver. Hepatology 1999;29:677–687.
407. Diehl AM, Li ZP, Lin HZ, et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005;54:303–306.
408. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway. Hepatology 2004;40:185–194.
409. Leclercq IA, Farrell GC, Sempoux C, et al. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004;51:926–934.
410. Moseley RH. Progress in understanding the pathogenesis of nonalcoholic fatty liver disease. Hepatology 2005;41:204–206.
411. Farrell GC. Signaling links in the liver: knitting SOCS with fat and inflammation. J Hepatol 2005;43:193–196.
412. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 2005;11:183–190.
413. Goldfine AB, Kahn CR. Adiponectin: linking the fat cell to insulin sensitivity. Lancet 2003;362:1431–1432.
414. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant gene transcript 1). Biochem Biophys Res Commun 1996;221:286–296.
415. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746–26749.
416. Hu E, Liang P, Spiegelman BM. Adipo Q is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697–10703.
417. Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996;120:802–812.
418. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.
419. Vuppalanchi R, Marri S, Kolwankar D, et al. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis. J Clin Gastroenterol 2005;39:237–242.
420. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 2004;40:46–54.
421. Masaki T, Chiba S, Tatsukawa T, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-α in KK-Ay obese mice. Hepatology 2004;40:177–184.
422. Czaja MJ. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 2004;40:19–22.
423. Kowdley KV, Pratt DS. Adiponectin – tipping the scales from NAFLD to NASH? Gastroenterology 2005;128:511–513.
424. Friedman JM. Obesity in the new millennium. Nature 2000;404:632–634.
425. Auwerx J, Staels B. Leptin. Lancet 1998;351:737–742.
426. Kaplan LM. Leptin, obesity and liver disease. Gastroenterology 1998;115:997–1001.
427. Ockenga J, Bischoff SC, Tillman HL, et al. Elevated bound leptin correlates with energy expenditure in cirrhotics. Gastroenterology 2000;119:1656–1662.
428. Rolland V, Clement K, Dugail I, et al. Leptin receptor gene in a large cohort of massivley obese subjects: no indication of the fa/fa rat mutation. Detection of an intronic variant with no association with obesity. Obes Res 1998;6:122–127.
429. Uygen A, Kadayifci A, Yesilova Z, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000;95:3584–3589.
430. Giannini E, Ceppa P, Botta F, et al. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2000;95:3211–3217.
431. Petroni ML, Pazzi P, Lucantoni R, et al. Determinants of raised aminotransferases in obesity: relation to insulin resistance and serum leptin. Gastroenterology 2001;116:A571.
432. Faggioni R, Jones-Carson J, Reed DA, et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A 2000;97:2367–2372.
433. Potter JJ, Womack L, Mezey E, et al. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 1998;244:178–182.
434. Angulo P, Alba LM, Petrovic LM, et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004;41:943–949.
435. Arias IM. The hepatocyte organization. In: Arias IM, Jacoby WB, Popper H, et al., eds. The liver: biology and pathobiology, 2nd ed. New York: Raven Press, 1988:9.
436. Phillips MJ, Poucell S, Patterson J, et al. The liver: an atlas and text of ultrastructural pathology. New York: Raven Press, 1987:45–46.
437. Lapis K, Schaff Z. Acute viral hepatitis. In: Johannessen JV, ed. Electron microscopy in human medicine, The liver vol 8. New York: McGraw-Hill, 137–157.
438. Caldwell SH, Redick JA, Chang CY, et al. Enlarged hepatocytes in NAFLD examined with osmium fixation:does microsteatosis underlie cellular balloning in NASH? Am Journal Gastroenterology 2006;101:1677.
439. Riley NE, Li J, McPhaul LW, et al. Heat shock proteins are present in mallory bodies (cytokeratin aggresomes) in human liver biopsy specimens. Exp Mol Pathol 2003;74:168–172.
440. Feldstein AE, Canby A, Angulo P, et al. Hepatocyte apoptosis and FAS expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437–443.
441. Feldman G, Haouzi D, Moreau A, et al. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in FAS-mediated hepatic apoptosis in mice. Hepatology 2000;31:674–683.
442. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309–1321.
443. Rashid A, Wu T-C, Huang C-C, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 1999;29:1131–1138.
444. Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology 2005;129:351–360.
445. Vendemiale G, Grattagliano I, Caraceni P, et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology 2001;33:808–815.
446. Fukumory T, Ohkohchi S, Tsukamoto S, et al. Why is fatty liver unsuitable for liver transplantation? Deterioration of mitochondrial ATP synthesis and sinusoidal atructure during cold preservation of a liver with steatosis. Transplant proc 1997;29:412–415.
447. Caldwell SH, Chang CY, Nakamoto RK, et al. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:595–618.
448. Chedid A, Mendenhall CL, Tosch T, et al. The Veterans Administration Cooperative Study of Alcoholic Hepatitis. Significance of megamitochondria in alcoholic liver disease. Gastroenterology 1986;90:1858–1864.
449. Petersen P. Abnormal mitochondria in hepatocytes in human fatty liver. Acta Pathol Microbiol Scand 1977;85:413–420.
450. Norum ML, French SW, Fredricks G, et al. Cytoplasmic crystalline inclusions in the hepatocytes of alcoholics. Gastroenterology 1972;62:606–611.
451. Sternlieb I, Berger JE. Optical diffraction studies of crystalline structure in electron micrographs. J Cell Biol 1969;43:448–455.
452. Krahenbuhl S. Alterations in mitochondrial function and morphology in chronic liver disease: pathogenesis and potential for therapeutic intervention. Pharmacol Ther 1993;60:1–38.
453. Pessayre D, Berson A, Fromenty D, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57–69.
454. Selzner M, Rudiger HA, Sindram D, et al. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 2000;32:1280–1288.
455. Marsman WA, Weisner RH, Rodriguez L, et al. Use of fatty donor liver is associated with diminished early patients and graft survival. Transplantation 1996;62:1246–1251.
456. Rinella ME, Alonsa E, Rao S, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001;7:409–414.
457. Miki C, Iriyama K, Mirza DF, et al. Post-perfusion energy metabolism of steatotic graft viability following liver transplantation. Dig Dis Sci 1998;43:74–79.
458. Chen J, Schenker S, Frosto TA, et al. Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme catalytic site. Biochem Bioph Acta 1998;1380:336–344.
459. Perez-Carrera M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38:999–1007.
460. Diehl AM, Hoek JB. Mitochondrial uncoupling: role of uncoupling protein anion carriers and relationship to thermogenesis and weight control “the benefits of losing control”. J Bioenerg Biomembr 1999;31:493–506.
461. Caraceni P, Bianchi C, Domenicali M, et al. Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. J Hepatol 2004;41:82–88.
462. Peralta C, Rosello-Catafau J. The future of fatty livers. J Hepatol 2004;41:149–151.
463. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005;42:928–940.
464. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998;27:128–133.
465. Ekstrom G, Ingelman-Sundberg M. Rat-liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450 IIE1). Biochem Pharmacol 1989;38:1313–1319.
466. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27–41.
467. Yoo JS, Ning SM, Pantuck EJ, et al. Regulation of hepatic microsomal cytochrome P450 2E1 level by dietary lipids and carbohydrates in rats. J Nutr 1991;121:959–965.
468. Niemela O, Parkkila S, Juvonen RO, et al. Cyotchromes P450 2 A6, 2 E1, and 3A and production of protein-aldehyde adducts in the liver patients with alcoholic and non-alcoholic liver disease. J Hepatol 2000;33:893–901.
469. Schattenberg JM, Wang Y, Rigoli RM, et al. CYP2E1 over expression alters hepatocyte death from mendione and fatty acids by activation of ERK1/2 signaling. Hepatology 2004;39:444–455.
470. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000;105:1067–1075.
471. Bardag-Gorce F, Wilson L, Nan L, et al. CYP2E1 inhibition enhances mallory body formation. Exp Mol Pathol 2005;78:207–211.
472. Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis. Clin Liver Dis 2004;8:639–671.
473. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909–916.
474. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002;35:898–904.
475. Koruk M, Sava MC, Yilmer O, et al. Serum lipids, lipoproteins and apolipoprotein levels in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003;37:177–182.
476. Cairns SR, Peters TJ. Micromethods for quantitative lipid analysis of human liver needle biopsy specimens. Clin Chim Acta 1983;127:373–382.
477. Cairns SR, Peters TJ. Isolation of micro- and macro-droplet fractions from needle biopsy specimens of human liver and determination of the subcellular distribution of the accumulating liver lipids in alcoholic fatty liver. Clin Sci 1984;67:337–345.
478. Moser AB, Jones DS, Raymond GV, et al. Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochem Res 1999;24:187–197.
479. Fournier B, Smeitink JAM, Dorland L, et al. Peroxisomal disorders: a review. J Inherit Metab Dis 1994;17:470–486.
480. Fan CY, Pan J, Usuda N, et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. J Biol Chem 1998;273:15639–15645.
481. De Craemer D, Pauwels M, Van den Branden C. Alterations of peroxisomes in steatosis of the human liver: a quantitative study. Hepatology 1995;22:744–752.
482. Rao MS, Reddy JK. Peroxisomal beta oxidation and steatohepatitis. Semin Liver Dis 2001;21:43–55.
483. Peters RL, Gay T, Reynolds TB. Post-jejunoileal bypass hepatic injury. Its similarity to alcoholic liver disease. Am J Clin Pathol 1975;63:318–331.
484. Yost RL, Duerson MC, Russell WL, et al. Doxycycline in the prevention of hepatic dysfunction: an evaluation of its use following jejunoileal bypass in humans. Arch Surg 1979;114:931–934.
485. Hamilton RL, Vest TK, Brown BS, et al. Liver injury with alcoholic-like hyaline after gastroplasty for morbid obesity. Gastroenterology 1983;85:722–726.
486. Beaugrand M, Denis J, Callard P. Tous les inhibiteurs calciques puevent-il entrainer des lesion d’hepatite alcoolique? Gastroenterol Clin Biol 1987;1:76.
487. Babany G, Uzzan F, Larrey D, et al. Alcohol-like liver lesions induced by nifedipine. J Hepatol 1989;9:252–255.
488. Dahl MG, Gregory MM, Scheuer PJ. Liver damage due to methotrexate in patients with psoriasis. BMJ 1971;1:625–630.
489. Cai Q, Bensen M, Greene R, et al. Tamoxiphen-induced transient multifocal hepatic fatty infiltration. Am J Gastroenterol 2000;95:277–279.
490. Pinto HC, Baptista A, Camilo ME, et al. Tamoxifen-associated steatohepatitis – report of three cases. J Hepatol 1995;23:95–97.
491. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344:1997–2008.
492. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. Ann Intern Med 1995;123:236.
493. Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis. Ann Intern Med 1996;124:855–856.
494. Oien KA, Moffat D, Curry GW, et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999;353:36–37.
495. Simon J, Manley P, Brien J, et al. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984;311:167–172.
496. Pirovino M, Muller O, Zysset T, et al. Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model. Hepatology 1988;8:591–598.
497. Lewis JH, Mullick F, Ishak KG, et al. Histopathological analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990;21:59–67.
498. Morris AAM, Carr A. HIV nucleoside analogues: new adverse effects on mitochondria? Lancet 1999;354:1046–1047.
499. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-l-protease inhibitor-associated peripheral lipodystrophy., hyperlipidemia, and insulin resistance. Lancet 1998;351:1881–1883.
500. Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDS 2005;19:356–365.
501. Dieterich DT, Robinson PA, Love J, et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004;38:S80–S89.
502. Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000;133:192–196.
503. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417–422.
504. Desai N, Mathur M, Weedon J. Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy. AIDS 2003;17:1565–1568.
505. Baker AL, Rosenberg IH. Hepatic complications of total parenteral nutrition. Am J Med 1987;82:489–497.
506. Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000;132:525–532.
507. Kaminski DL, Adams A, Jellinek M. The effect of hyperalimentation on hepatic lipid content and lipogenic enzyme activity in rats and man. Surgery 1980;88:93–100.
508. Quigley EM, Zetterman RK. Hepatobiliary complications of malabsorption and malnutrition. Semin Liver Dis 1988;8:218–228.
509. Naschitz JE, Yeshurun D, Zuckerman E, et al. Massive hepatic steatosis complicating adult coeliac disease. Report of a case and review of the literature. Am J Gastroenterol 1987;82:1186–1189.
510. Cassagnou M, Boruchowicz A, Guillemot F, et al. Hepatic steatosis revealing celiac disease by transitory liver failure. Am J Gastroenterol 1996;91:1291–1292.
511. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206–211.
512. Bardella MT, Valenti L, Pagliari C, et al. Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Dig Liver Dis 2004;36:333–336.
513. Nehra V, Angulo P, Buchman AL, et al. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci 2001;46:2347–2352.
514. Cullen JM, Ruebner BH. Histopathologic classification of chemical-induced injury of the liver. In: Meeks RG, Harrison SD, Bull RJ, eds. Hepatotoxicology. Boca Raton, FL: CRC Press, 1991.
515. Redlich CA, West AB, Fleming L, et al. Clinical and pathological characteristics associated with occupational exposure to dimethylformamide. Gastroenterology 1990;99:748–757.
516. Brodkin CA, Daniell W, Checkoway H, et al. Hepatic ultrasonic changes in workers exposed to perchloroethylene. Occup Environ Med 1995;52:679–685.
517. Redlich CA, Cullen MR. Nonalcoholic steatohepatitis. Ann Intern Med 1997;127:410.
518. Cotrim HP, Andrade ZA, Parana R, et al. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 1999;19:263–264.
519. Cotrim HP, Carvalho F, Siqueira AC, et al. Nonalcoholic fatty liver and insulin resistance among petrochemical workers. JAMA 2005:;294:1618–1620.
520. Sternlieb I. Copper and the liver. Gastroenterology 1980;78:1615–1628.
521. Scheinberg IH, Sternlieb I. Wilson disease and idiopathic copper toxicosis. Am J Clin Nutr 1996;63:842S–845S.
522. Thomas GR, Forbes JR, Roberts EA, et al. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995;9:210–217.
523. Mansouri A, Gaou I, Fromenty B, et al. Premature oxidative aging of hepatic mitochondrial DNA in Wilson’s disease. Gastroenterology 1997;113:599–605.
524. Balistreri WF, Schubert WK. Liver disease in infancy and childhood. In: Schiff L, Schiff ER, eds. Diseases of the Liver, 7th ed. Philadelphia, PA: JB Lippincott Co, 1993.
525. Smetana HF, Olen E. Hereditary galactose disease. Am J Clin Pathol 1962;38:3.
526. Russo P, O’Regan S. Visceral pathology of hereditary tyrosinemia type 1. Am J Hum Genet 1990;47:317–324.
527. Tarugi P, Lonardo A, Ballarini G, et al. Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. Gastroenterology 1996;111:1125–1133.
528. Lonardo A, Tarugi P, Ballarini G, et al. Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy and hepatocellular carcinoma. A case report. Dig Dis Sci 1998;43:2489–2492.
529. Burt AD, MacSween RNM, Peters TJ, et al. Nonalcoholic fatty liver: causes and complications. In: Oxford textbook of clinical hepatology, McIntyre N, ed. Oxford: Oxford University Press, 1991:863–872.
530. Westphal J-F, Brogard J-M. Drug administration in chronic liver disease. Drug Saf 1997;17:47–73.
531. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002;34:255–262.
532. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221–1231.
533. Acosta RC, Molina EG, O’Brien CB, et al. The use of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology 2001;120:A546.
534. Sanyal AJ, Mofrad PS, Contos MJ, et al. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107–1115.
535. Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol 2003;1:384–387.
536. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003;38:1008–1017.
537. Tiikkainen M, Hakkinen A-M, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169–2176.
538. Coyle WJ, Delaney N, Yoshihashi A, et al. Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTs and improve histology. Gastroenterology 1999;116:A1198.
539. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893–894.
540. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004;8:549–558.
541. Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;20:23–38.
542. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537–544.
543. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082–1090.
544. Guma G, Viola L, Thome M, et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial. Hepatology 1997;26:A387.
545. Ceriani R, Brunati S, Morini L, et al. Effect of ursodeoxycholic acid plus diet in patients with nonalcoholic steatohepatitis. Hepatology 1998;28:A386.
546. Laurin J, Lindor KD, Crippen JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996;23:1464–1467.
547. Mendez-Sanchez N, Gonzalez V, Pichardo-Bahena R, et al. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease: a double-blind, randomized, placebo-controlled trial. Hepatology 2000;32:A412.
548. Santos VN, Lanzoni VP, Szenfel J, et al. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. Braz J Med Biol Res 2003;36:723–729.
549. Bauditz J, Schmidt J, Dippe P, et al. Non-alcohol induced steatohepatitis in non-obese patients: treatment with ursodeoxycholic acid. Am J Gastroenterol 2004;99:959–960.
550. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770–778.
551. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734–738.
552. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor β-1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001;15:1667–1672.
553. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and Vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485–2490.
554. Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413–419.
555. Vajro P, Mandato C, Franzese A, et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004;38:48–55.
556. Kawanaka M, Mahmood S, Niiyama G, et al. Control of oxidative stress and reduction in biochemical markers by Vitamin E treatment in patients with nonalcoholic steatohepatitis: a pilot study. Hepatol Res 2004;29:39–41.
557. Feldstein AE, Papouchado BG, Angulo P, et al. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2005;3:384–389.
558. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001;21:81–88.
559. Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Dig Dis 1999;17:80–89.
560. Caldwell SH, Kowdley KV. Treating NAFLD: future prospects. J Clin Gastroenterol 2005;39(Suppl 4):S323.
561. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subject with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.
562. US Preventive Task Force. Screening for obesity in adults: recommendations and rationale. Ann Intern Med 2003;139:930–932.
563. McTigue KM, Harris R, Hemphill B, et al. Screening and interventions for obesity in adults: summary of evidence for the US preventive services task force. Ann Intern Med 2003;139:933–949.
564. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diab Care 2002;25:S50–S60.
565. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced or exercise-induced weight loss in men. A randomized controlled trial. Ann Intern Med 2000;133:92–103.
566. Bertram SR, Venter I, Stewart RI. Weight loss in obese women – exercise versus dietary education. S Afr Med J 1990;78:15–18.
567. Hoppeler H. Skeletal muscle substrate metabolism. Int J Obes 1999;23:S7–S10.
568. Van Baak MA. Exercise training and substrate utilization in obesity. Int J Obes 1999;23:S11–S17.
569. Seip RL, Snead D, Pierce EF, et al. Perceptual responses and blood lactate concentration: effect of training state. Med Sci Sports Exerc 1991;23:80–87.
570. Duncan G, Perri M, Theriaque D, et al. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously healthy adults. Diab Care 2003;26:557–562.
571. Frank LL, Sorensen BE, Yasui Y, et al. Effects of exercise on metabolic risk variables in overweight postmenopausal women: a randomized clinical trial. Obes Res 2005;13:615–625.
572. Nishizawa T, Akaoka I, Nishida Y, et al. Some factors related to obesity in the Japanese sumo wrestler. Am J Clin Nutr 1976;29:1167–1174.
573. Keeffe EB, Adesman PW, Stenzel P, et al. Steatosis and cirrhosis in an obese diabetic resolution of fatty liver by fasting. Dig Dis Sci 1987;32:441–445.
574. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408–1412.
575. Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 2005;39:S295–S299.
576. Rozental P, Biava C, Spencer H, et al. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967;12:198–208.
577. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970;282:829–834.
578. Guichard-Rode S, Charrie A, Penet D, et al. Massive weight loss does not restore normal insulin secretory pulses in obese patients with type 2 (non-insulin dependent) diabetes mellitus. Diab Metab 1997;23:506–510.
579. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986;220:83–88.
580. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072–1081.
581. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103–107.
582. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413–419.
583. Wang RT, Koretz RL, Yee HF. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003;115:554–559.
584. Franzese A, Vajro P, Argenziano A, et al. Liver Involvement in obese children ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997;42:1428–1432.
585. Vajro P, Fontanella A, Perna C, et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994;125:239–240.
586. Vessby B. Dietary fat and insulin action in humans. Br J Nutr 2000;83:S91–S96.
587. Borkman M, Storlien LH, Pan DA, et al. The relationship between insulin sensitivity and the fatty acid composition of skeletal muscle. N Engl J Med 1993;328:238–244.
588. Lokesh B, LiCari J, Kinsella JE. Effect of different dietary triglycerides on liver fatty acids and prostaglandin synthesis by mouse peritoneal cells. J Parenteral Enteral Nutr 1992;16:316–321.
589. Lanza-Jacoby S, Smythe C, Phetteplace H, et al. Adaptation to a fish oil diet before inducing sepsis in rats prevents fatty infiltration of the liver. J Parenteral Enteral Nutr 1992;16:353–358.
590. Zheng X, Rivabene R, Cavallari C, et al. The effects of chylomicron remnants enriched in n-3 or n-6 polyunsaturated fatty acids on the transcription of genes regulating their uptake and metabolism by the liver: influence of cellular oxidative state. Free Radic Biol Med 2002;32:1123–1131.
591. O’Keefe JH, Harris WS. Omega-3 fatty acids: time for clinical implementation? Am J Cardiol 2000;85:1239–1241.
592. Kurihara T, Adachi Y, Yamagata M, et al. Role of eicosapentanoic acid in lipid metabolism in the liver with special reference to experimental fatty liver. Clin Ther 1994;16:830–837.
593. Nanji AA, Sadrzadeh SMH, Yang EK, et al. Dietary saturated fatty acids: a novel treatment for alcoholic liver disease. Gastroenterology 1995;109:547–554.
594. Ip E, Farrell GC, Roberston G, et al. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003;38:123–132.
595. Fernandez MI, Torres MI, Gil A, et al. Steatosis and collagen content in experimental liver cirrhosis are affected by dietary monounsaturated and polyunsaturated fatty acids. Scand J Gastroenterol 1997;32:350–356.
596. Cortez-Pinto H, Zhi Lin H, Qi Yang S, et al. Lipids up-regulate uncoupling protein-2 expression in rat hepatocytes. Gastroenterology 1999;116:1184–1193.
597. Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003;38:1529–1539.
598. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004;39:608–616.
599. Tsubyama-Kasaoka N, Miyazaki H, Kasaoka S, et al. Increasing the amount of fat in a conjugated linoleic acid-supplemented diet reduces lipodystrophy in mice. J Nutr 2003;133:1793–1799.
600. Capanni M, Callela F, Centenaro R, et al. Prolonged N-3 PUFA dietary supplementation improves fatty liver in patients with NAFLD. J Hepatol 2004;40:S168.
601. Hatzitolios A, Savopoulos C, Lazarki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004;23:131–134.
602. Trebble T, Arden NK, Stroud MA, et al. Inhibition of tumor necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to anti-oxidant co-supplementation. Br J Nutr 2003;90:405–412.
603. Harrison SA, Ramrakhiani S, Brunt EM, et al. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003;98:926–930.
604. Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623–628.
605. Sabuncu T, Nazligul Y, Karaoglanoglu M, et al. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003;12:189–192.
606. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001;120:669–681.
607. Shaffer EA. Bariatric surgery: a promising solution for nonalcoholic steatohepatitis in the very obese. J Clin Gastroenterol 2005;39:S300–S306.
608. Dixon JB, Bhathal PS, Hughes NR, et al. Non-alcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647–1654.
609. Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48–58.
610. Srivastava S, Younossi ZM. Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery. Hepatology 2005;42:490–492.
611. Heuman DM, Pandak WM, Hylemon PB, et al. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991;14:920–926.
612. Heuman DM, Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994;106:1333–1341.
613. Heuman DM, Bajaj RS, Lin Q. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection. J Lipid Res 1996;37:562–573.
614. Trauner M, Graziadei W. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 1999;13:979–995.
615. Kurihara T, Akimoto M, Abe K, et al. Inhibitory effect of ursodeoxycholic acid on the progression of chronic hepatic disorders with special reference to increases in blood flow. Clin Ther 1993;15:866–874.
616. Rodrigues CM, Fan G, Ma X, et al. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998;101:2790–2799.
617. Clark JM, Brancati FL. Negative trials in nonalcoholic steatohepatitis: why they happen and what they teach us. Hepatology 2004;39:602–603.
618. Dufour J-F, Oneta C, Gonvers J-J, et al. A 2-years multicenter randomized placebo-controlled study testing UDCA in combination with vitamin E to treat NASH. J Hepatol 2005;42:S4.
619. Obinata K, Maruyama T, Hayashi M, et al. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 1996;403:607–613.
620. Simon JB, Scheig R, Klatskin G. Protection by orotic acid against the renal necrosis and fatty liver of choline deficiency. Proc Soc Exp Biol Med 1968;129:874–877.
621. Chang CY, Argo CK, Al-Osaimi AMS, et al. Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol 2005;39(Suppl 4):S307–S316.
622. Saldeen T, Li D, Mehta JL. Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol 1999;34:1208–1215.
623. Liu M, Wallin R, Wallmon A, et al. Mixed tocopherols have a stronger inhibitory effect on lipid peroxidation than alpha-tocopherol alone. J Cardiovasc Pharmacol 2002;39:714–721.
624. Chen H, Li D, Saldeen T, et al. Mixed tocopherol preparation is superior to alpha-tocopherol alone against hypoxia-reoxygenation injury. Biochem Biophys Res Commun 2002;291:349–353.
625. Brigelius-Flohe R, Traber MG. Vitamin E: function and metabolism. Faseb J 1999;13:1145–1155.
626. Antisiewicz J, Nishizawa Y, Liu X, et al. Suppression of the hydrazine-induced formation of megamitochondria in the rat liver by α-tocopherol. Exp Mol Pathol 1994;60:173–187.
627. Soltys K, Dikdan G, Koneru B. oxidative stress in fatty liver of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. Hepatology 2001;34:13–18.
628. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, anti-oxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583–1592.
629. Miller ER III, Pastor-Barriuso R, Dalal D, et al. Meta-Analysis: high-dosage Vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37–46.
630. Adams LA, Angulo P. Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol 2003;98:2348–2350.
631. Neuschwander-Tetri BA. Betaine: an old therapy for a new scourge. Am J Gastroenterol 2001;96:2534–2536.
632. Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711–2717.
633. Alvaro D, Gigliozzi A, Piat C, et al. Effect of S-adenosyl-L-methionine on ethanol cholestasis and hepatotoxicity in isolated perfused rat liver. Dig Dis Sci 1995;40:1592–1600.
634. Lu S. Methionine adenosyltransferase and liver disease: It’s all about SAM. Gastroenterology 1998;114:403–407.
635. Colell A, garcia-Ruiz C, Morales A, et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-methionine. Hepatology 1997;26:699–708.
636. Venkataramanan R, Ramachandran V, Komoroski BJ, et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000;28:1270–1273.
637. Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2003;18:1220–1221.
638. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992;102:1363–1370.
639. Demetriou AA. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. J Parenteral Enteral Nutr 1992;16:487–488.
640. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease. Hepatology 2003;37:343–350.
641. Villa RF, Gorini A. Pharmacology of lazaroids and brain energy metabolism: a review. Pharmacol Rev 1997;49:99–136.
642. Caldwell SH, Argo CK, Al-Osaimi AMS. Therapy of NAFLD: insulin sensitizing agents. J Clin Gastroenterol 2005;39(Suppl 4):S317–S322.
643. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281–303.
644. Sinha A, Formica C, Tsalamandris C, et al. Effect of insulin on body composition in patients with insulin-dependant and non-insulin-dependent diabetes. Diabet Med 1996;13:40–46.
645. Santomauro ATMG, Boden G, Sliva MER, et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999;48:1836–1841.
646. Nestler JE, Jakubowicz DJ, Iuorno MJ. Role of inositolphosphoglycan mediators of insulin action in the polycyctic ovary syndrome. J Pediatr Endocrinol 2000;13(Suppl 5):1295–1298.
647. Gallwitz B. Glucagon-like Peptide-1 as a treatment option for type 2 diabetes and its role in restoring Beta-cell mass. Diab Technol Ther 2005;7:651–657.
648. Shulman AI, Mangelsdorf DJ. Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med 2005;353:604–615.
649. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354:141–148.
650. Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diab Care 1999;22:288–293.
651. Katoh S, Hata S, Matsushima M, et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy – a randomized controlled trial. Metabolism 2001;50:414–417.
652. Shimaya A, Kurosaki E, Shiodola K, et al. YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes. Horm Metab Res 1998;30:543–548.
653. Lenhard JM, Kliewer SA, Paulik MA, et al. Effects of troglitazone and metformin on glucose and lipid metabolism. Biochem Pharmacol 1997;54:801–808.
654. Aubert J, Champigny O, Saint-Marc P, et al. Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Biochem Biophys Res Commun 1997;238:606–611.
655. Shimabukuro M, Zhou YT, Levi M, et al. Fatty acid induced beta cell apoptosis: a link between obesity and diabetes. Proc Nat Acad Sci U S A 1998;95:2498–2502.
656. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61–71.
657. Argo CK, Northup PG, Al-Osaimi AMS, et al. Long-term Follow-up of troglitazone therapy in nonalcoholic steatihepatitis. Gasteroenterology 2006;130:A825.
658. Caldwell S, Iezzoni J. Longterm follow-up of NASH patients treated with trogliazone. (submitted for publication).
659. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003;38:434–440.
660. Ono M, Ikegami H, Fujisawa T, et al. Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. Metab Clin Exp 2005;54:529–532.
661. Harrison S, Belfort R, Brown K, et al. A double-blind, placebo controlled trial of pioglitazone in the treatment of nonalcoholic steatohepatitis (abstract). Gastroenterology 2005;128:A1.
662. Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 1998;129:38–41.
663. Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998;129:36–38.
664. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;338:916–917.
665. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000;132:118–121.
666. Al-Salman J, Arjomond H, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone. Ann Intern Med 2000;132:121–124.
667. May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002;136:449–452.
668. Caldwell SH, Hespenheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 2001;46:376–378.
669. Kennedy FP. Do thiazolidinediones cause congestive heart failure? Mayo Clin Proc 2003;78:1076–1077.
670. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: consensus statement from the American Heart Association and the American Diabetes Association. Circulation 2003;108:2941–2948.
671. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265–266.
672. Kirpichnikov D, McFarlane SI, Sowers JI. Metformin: an update. Ann Intern Med 2002;137:25–33.
673. Argaud D, Roth H, Wiernsperger N, et al. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Eur J Biochem 1993;213:1341–1348.
674. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and glucose production. Diabetes 1994;43:920–928.
675. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167–1174.
676. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses nonalcoholic fatty liver disease in obese leptin-deficient mice. Nat Med 2000;6:998–1003.
677. Magalotti D, Marchesini G, Ramilli S, et al. Splanchnic hemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment: a pilot study. Dig Liver Dis 2004;36:406–411.
678. Bailey CJ. Biguanides and NIDDM. Diab Care 1992;15:755–772.
679. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999;31:384.
680. Saibara T, Onishi S, Ogawa Y, et al. Bezafibrate for tamoxiphen-induced non-alcoholic steatohepatitis. Lancet 1999;353:1802.
681. Charles EC, Olson KL, Sandhoff BG, et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005;118:618–624.
682. Rallidis LS, Drakoulis CK. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004;174:193–196.
683. Horlander JC, Kwo PY, Cummings OW, et al. Atorvastatin for the treatment of NASH. Gastroenterology 2001;120:A544.
684. Choudhry NK, Avorn J. Over-the-counter statins. Ann Intern Med 2005;142:910–913.
685. Oben JA, Diehl AM. Sympathetic nervous system regulation of liver repair. Anat Rec Part A 2004;280:874–883.
686. Dulloo AG. A sympathetic defense against obesity. Science 2002;297:780–781.
687. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222–1225.
688. Nair S, Verma S, Thuluvath PJ. Obesity and the effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002;35:105–109.
689. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004;4:686–693.
690. Czaja AJ. Recurrence of nonalcoholic steatohepatitis after liver transplantation. Liver Transpl Surg 1997;3:185–186.
691. Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997;3:177–178.
692. Carson K, Washington MK, Treem WR, et al. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg 1997;3:174–176.
693. Kim WR, Poterucha JJ, Porayko MK, et al. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996;62:1802–1805.
694. Cassarino DS, Swerdlow RH, Parks JK, et al. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer’s disease cybrids. Biochem Biophys Res Commun 1998;248:168–173.
695. Fukumori T, Ohkohchi Nm, Tsukamoto S, et al. Why is the fatty liver unsuitable for transplantation? Deterioration of mitochondrial ATP synthesis and sinusoidal structure during cold preservation of a liver with steatosis. Transplant Proc 1997;29:412–415.
696. Trotter JF. Thin chance for fat people. Liver Transpl 2001;7:415–417.
697. Alwayn IPJ, Andersson C, Zauscher B, et al. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation 2005;79:606–608.